OpenAI Backs Brain Implant Startup for Cancer Detection
Original: OpenAI Invests in Startup That Uses Brain Implants to Detect Cancer
Why This Matters
AI giants are moving into neural data, blurring lines between tech and biomedical research.
OpenAI's VC arm and Founders Fund co-led a $45M seed round in Coherence Neuro, a San Francisco startup building brain implants to detect and treat cancer using AI-decoded neural signals.
OpenAI's venture arm and Peter Thiel's Founders Fund have jointly invested in Coherence Neuro, a startup developing a brain implant that uses AI to detect and treat cancer. The $45 million seed round funds a device designed to read subtle electrical signals associated with brain tumors—identifying whether cancer is growing, shrinking, or recurring.
Coherence CEO Ben Woodington argues that brain-computer interface companies generate datasets too large for human analysis, making AI a natural fit. "The idea of capturing data to train better models and use it to optimize treatments is going to be super important," he said.
This summer, the company briefly tested its implant in three patients already undergoing brain tumor surgery at Royal Melbourne Hospital in Australia. The device remained in place for roughly 30 minutes as a safety check. Seven additional patients are now testing both recording and stimulation functions. The implant is designed to emit mild electrical stimulation to halt tumor growth, eventually learning to detect cancer signals and deliver real-time treatment.
Coherence plans to use the funding to launch a long-term clinical trial targeting glioblastoma, one of the most aggressive brain cancers. This investment follows OpenAI's January backing of Merge Labs, a brain-computer interface company cofounded by Sam Altman that raised $252 million.